Charles J. Ryan, MD
The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers. According to an international panel of genitourinary oncology experts, these advancements are enabling strategies tailored for individual patients, and at the same time, prompting a need for practitioners to expand their knowledge base.
During a recent OncLive Peer Exchange®
, leading investigators in the field discussed the concepts of clarification, classification, and personalization in prostate cancer, focusing on the role of recently approved second-generation antiandrogens in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and the use of chemotherapy and novel agents in those with metastatic disease.
They also discussed emerging findings about prognostic markers and genomic features, which provide additional insights on whom, when, and how to treat. “It’s not just about metastasis, yes or no; hormone resistance, yes or no. It’s high volume, low volume, BRCA2
, etc. It’s getting more complex, and it makes it more interesting. What’s great is that we now can speak with a little more clarity to our patients about the therapy options that they have,” panelist Charles J. Ryan, MD
, said.Daniel J. George, MD
, who served as moderator for the program, stressed the opportunity to personalize treatment by taking into consideration the differences in available therapies and the patient’s preferences, underlying physical fitness, and genomic profile. “It’s important to encompass all that into a treatment plan,” he said.
... to read the full story